CASE REPORTSLong-term use of pegylated liposomal doxorubicin to a cumulative dose of 4600 mg/m2 in recurrent ovarian cancerPendlebury, Adam; DeBernardo, Robert; Rose, Peter G.Author Information Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, USA Correspondence to Adam Pendlebury, MBBS, BMedSci, Cleveland Clinic Taussig Cancer Center, 9500 Euclid Avenue, A81, Cleveland, OH 44195, USA Tel: +1 216 444 1712; fax: +1 216 444 8551; e-mail: firstname.lastname@example.org Received November 16, 2016 Accepted May 2, 2017 Anti-Cancer Drugs: August 2017 - Volume 28 - Issue 7 - p 815-817 doi: 10.1097/CAD.0000000000000521 Buy Metrics Abstract Pegylated liposomal doxorubicin (PLD) is used widely in gynecologic oncology and other oncology disciplines. Native doxorubicin use is associated with the potential for significant toxicity. Cardiac toxicity in particular limits lifetime dose. PLD has not been shown to be associated with clinical cardiac toxicity. We report on the long-term use of PLD in a patient with recurrent high-grade serous ovarian cancer to a lifetime dose of 4600 mg/m2. This therapy was associated with long-term stable disease, good performance status, and minimal adverse effects. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.